Bacil Pharma Ltd

Directors appointed

• Mr. Mahesh Singh appointed as Additional Independent Director, effective 25 August 2026, subject to member approval.
• Mr. Anil Shiv Charan Singh appointed as Additional Non-Executive Director, effective 25 August 2026, subject to member approval.
• Directors submitted declarations; not debarred by SEBI or regulator.

Meeting Details

• Date: 25 August 2026; time/location not disclosed.

Key Agenda Items

• Discussion on appointment of directors.
• Any other business with chairperson's permission.

Other Notes

• No trading window details disclosed.

Quarterly results

• Total revenue for quarter ended 30-06-2026: ₹8.91 lakh.
• Profit before tax: ₹6.64 lakh for the quarter.
• Tax expense: current tax ₹0; deferred tax ₹8.25 lakh.
• Profit after tax (PAT) from ordinary activities: ₹-1.61 lakh.
• Total comprehensive income: ₹30.12 lakh; OCI ₹31.73 lakh.
• Earnings per share: Basic ₹0.22; Diluted ₹0.22.
• Employee benefits expense ₹0.72 lakh; Other expenses ₹1.55 lakh; Total expenses ₹2.27.
• The company has only one reportable primary pharmaceutical business segment.

Meeting Details

• Date: 12 August 2026; time and venue not disclosed.

Key Agenda Items

• Approval of unaudited financial results for the quarter ended 30 June 2026.
• Any other business with the permission of the Chairperson.

Other Notes

• Trading window closure periods not specified.

Subsidiary incorporation

• Bacil Pharma Ltd formed wholly owned subsidiary BACIL RESEARCH AND DEVELOPMENT PRIVATE LIMITED on 28 July 2026.
• CIN U72100MH2026PTC474072 assigned.
• PAN AAOCB9909L and TAN MUMB40406C provided.
• MCA certificate confirms incorporation under Companies Act, 2013.
• Wholly owned by Bacil Pharma Ltd.

Rights issue proposal

• Board approved rights issue of equity shares for up to ₹50 crore, subject to regulatory approvals.

Capital increase

• Board approved increase in authorised share capital by ₹45 crore, to ₹65 crore post-raise.

Intermediaries appointed

• Intermediaries appointed for Right Issue: Registrar Purva Sharegistry, Banker Axis Bank, Monitoring Agency Acuité.

Resignations

• Independent Directors Dinesh Chander Notiyal and Avani Godhaniya resigned effective 9 July 2026.

Right Issue Committee

• Right Issue Committee formed, with Chaitali Shah as Chair; two independent directors as members.

Signing authority

• Authority given to Chaitali Shah and Company Secretary for Rights Issue documentation.

Trading window

• Trading window remains closed until 48 hours after Rights Issue outcome.

Dematerialisation status

• Dematerialisation requests were processed and confirmed to the depositories as accepted or rejected.
• Dematerialised securities have been listed on the exchanges where the earlier issues are listed.
• Physical certificates were mutilated and cancelled after verification; depository name substituted within fifteen days.

Resignations of Independent Directors

• Dinesh Chander Notiyal resigned as Independent Director, effective 9 July 2026, due to time constraints.
• Avani Savjibhai Godhaniya resigned as Independent Director, effective 9 July 2026, due to time constraints.

Right Issue Committee Formed

• Right Issue Committee formed; Chair: Chaitali Kalpataru Shah (Executive Director & CFO).
• Members: Vivek Mukesh Yadav and Omprakash Pyarelal Sonar (Independent Directors).

Signing Authority for Right Issue

• Board authorised Chaitali Kalpataru Shah and Company Secretary to sign documents for Right Issue.

Intermediaries Appointed for Right Issue

• Registrar for Right Issue: Purva Sharegistry (INR000001112).
• Banker to the Issue: Axis Bank Limited (Sakinaka Branch, Mumbai).
• Monitoring Agency: Acuite Ratings & Research Limited.

Trading Window Closure

• Trading Window will remain closed for designated persons until 48 hours after outcome of the meeting.

Fund raising

• Rights Issue of equity shares up to ₹50 crore approved, subject to approvals.
• Issue to comply with Companies Act, SEBI ICDR, LODR and related laws.

Authorized capital increase

• Authorized Share Capital increased by ₹45 crore to ₹65 crore.
• Post-increase MOA and capital clause to be amended, subject to shareholder approval.

Rights issue intermediaries

• Registrar: Purva Sharegistry (India) Private Limited.
• Banker to the Issue: Axis Bank Limited, Sakinaka Branch.
• Monitoring Agency: Acuite Ratings & Research Limited.

Independent directors resignation

• Resignation of Independent Directors Dinesh Chander Notiyal and Avani Savjibhai Godhaniya approved.
• Effective date not specified.

Right Issue Committee

• Chaitali Kalpataru Shah (ED & CFO) to chair the Committee.
• Members: Vivek Yadav and Omprakash Sonar (Independent Directors).

Signatories for Rights Issue

• Chaitali Kalpataru Shah and Company Secretary authorized to sign and file Rights Issue documents.

Trading window

• Trading window remains closed for designated persons until 48 hours after outcome.

Rights Issue details

• Rights Issue up to ₹50 crore; equity shares to be listed subject to approvals.
• Offered to all eligible shareholders; promoter group may participate.

Name approval and incorporation status

• CRC approved the name 'Bacil Research & Development Private Limited' for the subsidiary.
• Incorporation is in progress; disclosure will follow after Certificate of Incorporation is issued.
• Name validity is 20 days from 06/07/2026, until 26/07/2026.